Project Name:
Reducing Excess Cardiovascular Risk in People with Serious Mental Illness

Principal Investigator:
Rebecca Rossom, MD

Principal Investigator Contact Information:

Principal Investigator institution:
HealthPartners, Minneapolis, MN


Funding Period:
08/2014 – 06/2019

People with serious mental illness (SMI) (schizophrenia, schizoaffective disorder, bipolar disorder) die, on average, 20 years earlier than their peers. Cardiovascular (CV) disease is the predominant cause.  Primary care providers (PCPs) are often unaware of increased risk in patients with SMI and, even when they do identify elevated CV risk factors, often do not take appropriate clinical actions.  Electronic medical record (EMR)-based clinical decision support (CDS) can identify at-risk patients with SMI and systematically prompt more effective treatment of their CV risk factors, but its potential has been largely untapped. 

Grant Number:

Participating Sites:
HealthPartners, Minneapolis, MN (Lead Site)
Essential Health, Duluth, MN
Park Nicollet, Minneapolis, MN                               

Rebecca Rossom, MD, MS     
Steve Waring, PhD
Patrick O’Connor, MD, MS, MA
JoAnn Sperl-Hillen, MD
Lauren Crain, PhD
Kris Kopski, MD, PhD
Pritika Kumar, PhD

The objectives of this project are to improve CV risk factor care in patients with SMI through a pragmatic trial of a point-of-care EMR-based CDS (referred to as “CV Wizard”).  The trial will be conducted in over 80 “real world” primary care clinics in three large healthcare systems.

Description of study sample:
Patients enrolled in the study are age 18-75 with schizophrenia, schizoaffective disorder or bipolar disorder, and not at goal for at least one of the following preventable cardiovascular risk factors: BMI, tobacco use, LDL, blood pressure, A1c or aspirin use.

Current Status:
The project has been implemented in all 3 sites and will complete patient enrollment at the end of September 2018.   Patient enrollment has exceeded the anticipated total.   

Study Registration: # NCT02451670



Lessons Learned:

What’s next?
Analyses and manuscript development have begun.